A recent article from Fierce Biotech highlights the world's top emerging biotech hubs for 2026, showcasing the regions attracting investment, innovation and the next generation of life sciences companies. As these biotech ecosystems continue to grow, proximity matters. With offices strategically located in London, Berlin, Philadelphia and Shanghai, Clinical Services International (CSI) is well positioned to support sponsors across many of these fast-growing life sciences hubs

Clinical Services International (CSI) is proud to reaffirm its commitment to the United Nations Global Compact (UNGC) following the successful submission of our 2025 Communication on Progress (CoP). As a participant in the world's largest corporate sustainability initiative, CSI continues to align its business operations with the Ten Principles of the UN Global Compact, covering human rights, labour, environmental responsibility and anti-corruption. Embedding Responsible Busi

We’re proud to announce that Clinical Services International (CSI) has been awarded the EcoVadis Platinum Medal for the third consecutive year. This recognition places us among the top 1% of companies assessed globally for sustainability and reflects our continued commitment to responsible business practices, ethical governance, environmental stewardship, and sustainable procurement. Achieving Platinum for three years in a row is a testament to the dedication of our entire te

End-to-end comparator sourcing built for speed, control, and reliability. We exist to remove risk, reduce cost, and keep clinical trials moving. Contact us and get a response within 48 hours:

Over the past few years, GLP-1 receptor agonists have moved from a niche diabetes treatment to one of the most in-demand drug classes globally. Medicines such as semaglutide and tirzepatide are now widely used not only for type 2 diabetes but increasingly for obesity and metabolic disease. Demand Is Outpacing Supply Global demand for GLP-1 therapies has surged due to increased global trial activity involving GLP-1 comparators, expanding indications and it’s increasing availab